Document is current
Any future updates will be listed below
-
Authors
Kaiser, Jaclyn A.
Nelson, Christine E. http://orcid.org/0000-0003-3879-9105
Liu, Xueqiao
Park, Hong-Su http://orcid.org/0000-0002-8423-2188
Matsuoka, Yumiko
Luongo, Cindy http://orcid.org/0000-0002-3830-3803
Santos, Celia
Ahlers, Laura R. H.
Herbert, Richard
Moore, Ian N.
Wilder-Kofie, Temeri
Moore, Rashida
Walker, April
Yang, Lijuan
Munir, Shirin http://orcid.org/0000-0002-8493-0728
Teng, I-Ting
Kwong, Peter D. http://orcid.org/0000-0003-3560-232X
Dowdell, Kennichi http://orcid.org/0000-0002-7034-711X
Nguyen, Hanh http://orcid.org/0000-0002-0080-8312
Kim, JungHyun
Cohen, Jeffrey I.
Johnson, Reed F.
Garza, Nicole L.
Via, Laura E. http://orcid.org/0000-0001-6074-9521
Barber, Daniel L. http://orcid.org/0000-0001-7008-7509
Buchholz, Ursula J. http://orcid.org/0000-0002-2329-3198
Le Nouën, Cyril http://orcid.org/0000-0002-5719-4112
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (ZIA AI001298-01, 1ZIAAI001294-04)
Vaccine Research Center, NIAID, NIH
- License Information
-
More Information
Article History
Received: 19 August 2023
Accepted: 11 April 2024
First Online: 26 April 2024
Competing interests
: J.A.K., C.L., S.M., C.L.N. and U.J.B. are inventors on the provisional patent application number 63/502,829 entitled “Recombinant murine pneumonia virus expressing severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike protein” filed by the United States, Department of Health and Human Services. The remaining authors declare no competing interests.
